Search

Search Constraints

You searched for: Author/Creator Fenstermaker, Robert

Search Results

1. 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer. (10th December 2020)

2. 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer. (9th November 2020)

3. ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma. (5th November 2018)

5. CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE). (14th November 2022)

6. CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA. (14th November 2022)

8. INNV-16. CLINICAL APPLICABILITY OF INDIVIDUALIZED DRUG RESPONSE PROFILING UTILIZING EX-VIVO TISSUE-DERIVED 3D CELL CULTURE ASSAYS IN HIGH-GRADE GLIOMA: A SINGLE INSTITUTION CASE SERIES USING 3D-PREDICT RESULTS. (9th November 2020)

9. INNV-33. FUNCTIONAL EX VIVO TESTING PROSPECTIVELY IDENTIFIES NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS SENSITIVE TO TEMOZOLOMIDE TREATMENT IRRESPECTIVE OF MGMT METHYLATION STATUS. (14th November 2022)